The effect of the thioether-bridged, stabilized angiotensin-(1-7) analogue cyclic Ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction

International Journal of Hypertension

Volumn 2012, Issue , 2012, Pages

  Durik, Matej ^a   Van Veghel, Richard ^a   Kuipers, Anneke ^b   Rink, Rick ^b   Haas Jimoh Akanbi, Marijke ^c,d   Moll, Gert ^b   Danser, A H Jan ^a   Roks, Anton J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LanthioPep   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN[1-7];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; BRAIN INFARCTION SIZE; CELL SIZE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STABILITY; ENDOTHELIAL DYSFUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART WEIGHT; LONG TERM CARE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; TREATMENT DURATION;

EID: 84861507620     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2012/536426     Document Type: Article

References (27)

1. Iusuf D., Henning R. H., van Gilst W. H., Roks A. J. M., Angiotensin-(17): pharmacological properties and pharmacotherapeutic perspectives. European Journal of Pharmacology 2008 585 2-3 303 312 2-s2.0-43049157967 10.1016/j.ejphar.2008.02.090
2. Ferreira A. J., Santos R. A. S., Bradford C. N., Mecca A. P., Sumners C., Katovich M. J., Raizada M. K., Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 2010 55 2 207 213 2-s2.0-74949087578 10.1161/HYPERTENSIONAHA.109.140145
3. Santos R. A. S., Simoes e Silva A. C., Maric C., Silva D. M. R., Machado R. P., De Buhr I., Heringer-Walther S., Pinheiro S. V. B., Lopes M. T., Bader M., Mendes E. P., Lemos V. S., Campagnole-Santos M. J., Schultheiss H. P., Speth R., Walther T., Angiotensin-(17) is an endogenous ligand for the G protein-coupled receptor Mas. Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8258 8263 2-s2.0-0037478671 10.1073/pnas.1432869100 (Pubitemid 36842532)
4. Loot A. E., Roks A. J. M., Henning R. H., Tio R. A., Suurmeijer A. J. H., Boomsma F., Van Gilst W. H., Angiotensin-(17) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002 105 13 1548 1550 2-s2.0-0037007055 10.1161/01.CIR.0000013847.07035.B9 (Pubitemid 34297630)
5. Wang Y., Qian C., Roks A. J. M., Westermann D., Schumacher S. M., Escher F., Schoemaker R. G., Reudelhuber T. L., Van Gilst W. H., Schultheiss H. P., Tschöpe C., Walther T., Circulating rather than cardiac angiotensin-(17) stimulates cardioprotection after myocardial infarction. Circulation 2010 3 2 286 293 2-s2.0-77951890433 10.1161/CIRCHEARTFAILURE.109.905968
6. Kucharewicz I., Pawlak R., Matys T., Pawlak D., Buczko W., Antithrombotic effect of captopril and losartan is mediated by angiotensin-(17). Hypertension 2002 40 5 774 779 2-s2.0-0036841147 10.1161/01.HYP.0000035396.27909.40 (Pubitemid 35278618)
7. Sampaio W. O., Dos Santos R. A. S., Faria-Silva R., Da Mata Machado L. T., Schiffrin E. L., Touyz R. M., Angiotensin-(17) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007 49 1 185 192 2-s2.0-33847018997 10.1161/01.HYP.0000251865. 35728.2f (Pubitemid 46360359)
8. Sampaio W. O., De Castro C. H., Santos R. A. S., Schiffrin E. L., Touyz R. M., Angiotensin-(17) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 2007 50 6 1093 1098 2-s2.0-36448975192 10.1161/HYPERTENSIONAHA.106.084848 (Pubitemid 350172931)
9. Qian C., Schoemaker R. G., van Gilst W. H., Roks A. J. M., The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function. Clinical Science 2009 116 4 301 314 2-s2.0-60549107875 10.1042/CS20080157
10. Kluskens L. D., Nelemans S. A., Rink R., De Vries L., Meter-Arkema A., Wang Y., Walther T., Kuipers A., Moll G. N., Haas M., Angiotensin-(17) with thioether bridge: an angiotensin- converting enzyme-resistant, potent angiotensin-(17) analog. Journal of Pharmacology and Experimental Therapeutics 2009 328 3 849 855 2-s2.0-62449281004 10.1124/jpet.108.146431
11. Langeveld B., Van Gilst W. H., Tio R. A., Zijlstra F., Roks A. J. M., Angiotensin-(17) attenuates neointimal formation after stent implantation in the rat. Hypertension 2005 45 1 138 141 2-s2.0-11244253741 10.1161/01.HYP. 0000149382.83973.c2 (Pubitemid 40066428)
12. Iwata M., Cowling R. T., Gurantz D., Moore C., Zhang S., Yuan J. X. J., Greenberg B. H., Angiotensin-(17) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. American Journal of Physiology 2005 289 6 H2356 H2363 2-s2.0-28144432331 10.1152/ajpheart.00317. 2005 (Pubitemid 41698543)
13. Grobe J. L., Mecca A. P., Lingis M., Shenoy V., Bolton T. A., Machado J. M., Speth R. C., Raizada M. K., Katovich M. J., Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(17). American Journal of Physiology 2007 292 2 H736 H742 2-s2.0-33846987938 10.1152/ajpheart.00937.2006
14. Durand M. J., Raffai G., Weinberg B. D., Lombard J. H., Angiotensin-(17) and low-dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries. American Journal of Physiology 2010 299 4 H1024 H1033 2-s2.0-77958035132 10.1152/ajpheart.00328.2010
15. Tesanovic S., Vinh A., Gaspari T. A., Casley D., Widdop R. E., Vasoprotective and atheroprotective effects of angiotensin (17) in apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 8 1606 1613 2-s2.0-77955175630 10.1161/ATVBAHA.110.204453
16. Rentzsch B., Todiras M., Iliescu R., Popova E., Campos L. A., Oliveira M. L., Baltatu O. C., Santos R. A., Bader M., Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 2008 52 5 967 973 2-s2.0-55949126600 10.1161/HYPERTENSIONAHA.108.114322
17. Rabelo L. A., Xu P., Todiras M., Sampaio W. O., Buttgereit J., Bader M., Santos R. A. S., Alenina N., Ablation of angiotensin (17) receptor Mas in C57Bl/6 mice causes endothelial dysfunction. Journal of the American Society of Hypertension 2008 2 6 418 424 2-s2.0-57149117137 10.1016/j.jash.2008.05.003
18. Peiró C., Vallejo S., Gembardt F., Azcutia V., Heringer-Walther S., Rodríguez-Mañas L., Schultheiss H. P., Sánchez-Ferrer C. F., Walther T., Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. Journal of Hypertension 2007 25 12 2421 2425 2-s2.0-35848966134 10.1097/HJH.0b013e3282f0143c (Pubitemid 350060381)
19. Xu P., Costa-Goncalves A. C., Todiras M., Rabelo L. A., Sampaio W. O., Moura M. M., Santos S. S., Luft F. C., Bader M., Gross V., Alenina N., Santos R. A. S., Endothelial dysfunction and elevated blood pressure in Mas gene-deleted mice. Hypertension 2008 51 2 574 580 2-s2.0-38549174602 10.1161/HYPERTENSIONAHA. 107.102764 (Pubitemid 351156450)
20. Langeveld B. E., Henning R. H., De Smet B. J. G. L., Zijlstra F., Driessen A., Tijsma E., Van Gilst W. H., Roks A. J. M., Rescue of arterial function by angiotensin-(17): towards improvement of endothelial function by drug-eluting stents. Netherlands Heart Journal 2008 16 9 293 298 2-s2.0-58149235049
21. Faria-Silva R., Duarte F. V., Santos R. A., Short-term angiotensin(17) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension 2005 46 4 948 952 2-s2.0-33644637224
22. de Vries L., Reitzema-Klein C. E., Meter-Arkema A., van Dam A., Rink R., Moll G. N., Akanbi M. H. J., Oral and pulmonary delivery of thioether-bridged angiotensin-(17). Peptides 2010 31 5 893 898 2-s2.0-77951254784 10.1016/j.peptides.2010.02.015
23. Iusuf D., Henning R. H., van Gilst W. H., Roks A. J. M., Angiotensin-(17): pharmacological properties and pharmacotherapeutic perspectives. European Journal of Pharmacology 2008 585 2-3 303 312 2-s2.0-43049157967 10.1016/j.ejphar.2008.02.090
24. Marques F. D., Ferreira A. J., Sinisterra R., Jacoby B. A., Sousa F. B., Caliari M. V., Silva G. A.B., Melo M. B., Nadu A. P., Souza L. E., Irigoyen M. C.C., Almeida A. P., Santos R. A.S., santos@icb.ufmg.br An oral formulation of angiotensin-(17) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 2011 57 3 477 483 10.1161/ HYPERTENSIONAHA.110.167346
25. Savergnini S. Q., Beiman M., Lautner R. Q., De Paula-Carvalho V., Allahdadi K., Pessoa D. C., Costa-Fraga F. P., Fraga-Silva R. A., Cojocaru G., Cohen Y., Bader M., De Almeida A. P., Rotman G., Santos R. A. S., Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the mas receptor. Hypertension 2010 56 1 112 120 2-s2.0-77953811506 10.1161/HYPERTENSIONAHA.110.152942
26. Ferreira A. J., Shenoy V., Yamazato Y., Sriramula S., Francis J., Yuan L., Castellano R. K., Ostrov D. A., Oh S. P., Katovich M. J., Raizada M. K., Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2009 179 11 1048 1054 2-s2.0-66249133083 10.1164/rccm.200811-1678OC
27. Ferreira A. J., Shenoy V., Qi Y., Fraga-Silva R. A., Santos R. A.S., Katovich M. J., Raizada M. K., mraizada@phys.med.ufl.edu Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Experimental Physiology 2011 96 3 287 294 10.1113/expphysiol.2010.055277